Sotrastaurin and tacrolimus coadministration: Effects on pharmacokinetics and biomarker responses

Journal of Clinical Pharmacology

Volumn 50, Issue 11, 2010, Pages 1260-1266

  Kovarik, John M ^a,b   Stitah, Sylvie ^a,b   Slade, Alan ^a,b   Vitaliti, Alessandra ^a,b   Straube, Frank ^a,b   Grenet, Olivier ^a,b   Winter, Serge ^a,b   Sfikas, Nikolaos ^a,b   Seiberling, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Swiss Pharma Contract ^*

Author keywords

drug interactions; Immunomodulators; protein kinase C; sotrastaurin; tacrolimus

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; INTERLEUKIN 2; MESSENGER RNA; PROTEIN KINASE C; SOTRASTAURIN; TACROLIMUS; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; ORGAN TRANSPLANTATION; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; CALCIUM; CELL PROLIFERATION; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; PROTEIN KINASE C; PYRROLES; QUINAZOLINES; RNA, MESSENGER; T-LYMPHOCYTES; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78449309302     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009360534     Document Type: Article

References (5)

1. Evenou J.-P, Wagner J., Zenke G., et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activity. J Pharmacol Experiment Ther. 2009 ; 330: 792-801.
2. Kovarik JM, Budde K., Pietruck F., et al. Steady-state pharmacokinetics of the protein kinase C inhibitor AEB071 in de novo kidney transplant patients [abstract]. Am J Transplant. 2008 ; 8 (suppl 2). 253.
3. Skvara H., Dawid M., Kleyn CE, et al. Potential therapeutic option for psoriasis with AEB071, a novel protein kinase C inhibitor. J Clin Invest. 2008 ; 118: 3151-3159.
4. Meier-Kriesche HU, Li S., Gruessner RWG, et al. Immunosuppression: evolution in practice and trends 1994-2004. Am J Transplant. 2006 ; 6 (part 2). 1111-1131.
5. Budde K., Sommerer C., Becker T., et al. AEB071, a novel protein kinase C inhibitor: first clinical results of an AEB071 plus tacrolimus regimen in renal transplant recipients [abstract]. Am J Transplant. 2009 ; 9 (suppl 2). 304.